Chemotherapy for recurrent ovarian cancer
- 1 June 2003
- journal article
- editorial
- Published by Elsevier in The Lancet
- Vol. 361 (9375), 2094-2095
- https://doi.org/10.1016/s0140-6736(03)13726-9
Abstract
No abstract availableThis publication has 6 references indexed in Scilit:
- First-line chemotherapy for ovarian cancer – the controversy continuesBritish Journal of Cancer, 2002
- First-line treatment for advanced ovarian cancer: paclitaxel, platinum and the evidenceBritish Journal of Cancer, 2002
- Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trialThe Lancet, 2002
- Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancerBritish Journal of Cancer, 2002
- Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosisNature Medicine, 1996
- Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compoundsGynecologic Oncology, 1990